It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates
Nerina Coppini, 4 October 2018

The creation of LAB031 is designed to translate academic research into drug discovery candidates Evotec aims to generate multiple lead candidates for Sanofi over three years across multiple therapeutic categories

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development
Nerina Coppini, 3 July 2018

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with...

Evotec achieves second milestone in diabetes alliance with Sanofi
Nerina Coppini, 25 June 2018

Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Evotec and Sanofi sign definitive agreement to combat infectious diseases
Nerina Coppini, 18 June 2018

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a next generation anti-infectives portfolio

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi
Nerina Coppini, 8 January 2018

Hamburg, Germany and Vienna, Austria, 08 January 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015. The milestone...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard